<div id="readability-page-1">Atossa Therapeutics, Inc. ( ATOS ) stock is trading higher on Thursday. Here’s what investors need to know. <ul> <li>Atossa Therapeutics ( ATOS ) shares are climbing with conviction. What’s driving ATOS stock higher?</li> </ul> What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The status is typically reserved for drug candidates that treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. The status gives (Z)-Endoxifen eligibility for a priority review voucher, which can be used to obtain priority review for a future application or may be sold or transferred to another sponsor. The drug candidate must first clear a qualifying marketing application. “This designation is an important regulatory milestone for Atossa, and we believe a strong validation of the science supporting the potential of (Z)-Endoxifen as a treatment for Duchenne Muscular Dystrophy,” said Steven Quay, CEO of the company. Atossa Therapeutics ( ATOS ) has not brought in revenue since 2016, according to Benzinga Pro. The company has reported a loss of 7 cents per share for the past two quarters. ATOS Price Action: Shares of Atossa were up 9.41%, trading at approximately 93 cents at the time of publication, according to Benzinga Pro. Read More: <ul> <li>Why Did Clearmind Medicine Shares Plunge 29% After Hours?</li> </ul> Image: Shutterstock</div>

ATOS

Atossa Therapeutics 的股票在 FDA 授予其潛在治療藥物 (Z)-Endoxifen 針對杜氏肌營養不良症的罕見兒童疾病認定後上漲了 9.41%。這一認定使其有資格獲得優先審查憑證，增強了該藥物未來申請的前景。首席執行官 Steven Quay 強調這是一個重要的監管里程碑。儘管自 2016 年以來未產生收入並報告虧損，但股票的上漲反映了投資者的樂觀情緒

為什麼 Atossa Therapeutics 的股票今天會上漲？